homeearnings News

Cipla Earnings Preview: US business to aid revenue growth in the mid teens

Cipla Earnings Preview: US business to aid revenue growth in the mid-teens

Cipla Earnings Preview: US business to aid revenue growth in the mid-teens
Read Time2 Min(s) Read
Profile image

By Ekta Batra  Jan 24, 2023 1:49:30 PM IST (Published)

Higher other income and better margin will also contribute to a 30 percent year-on-year growth in the Cipla's net profit.

wealth-desk wealth-desk

Buy / Sell Cipla share

Drugmaker Cipla is likely to report revenue growth in the mid-teens for the December quarter, led by a recovery in he US business.

Recommended Articles

View All

A CNBC-TV18 poll expects net profit to jump 30 percent while EBITDA margin may expand by 150 basis points.
US sales for Cipla were at a multi-quarter high of $175 million in the September quarter. For the current quarter, US sales are estimated to be in the range of $190 million - $214 million compared to $150 million during the same period last year.
Growth in the US business is likely to be led by a ramp up of its inhaler albuterol and volume limited sales of cancer drug Revlimid generic and Lanotirade.
Cipla's domestic business is likely to grow between 5-6 percent year-on-year on account of a higher base due to sale of Covid-19 drugs.
EBITDA margin will improve by 150 basis points over the year-ago period due to better US sales.
Higher other income and better margin will also contribute to a 30 percent year-on-year growth in the company's net profit.
Cipla's Goa unit continues to be classified as Official Action Indicated (OAI) status by the USFDA, based on the latest communication it has received from the regulator.
The US drug regulator may continue to withhold product approvals from Cipla's Goa facility until the outstanding observations are resolved, the company said in an exchange filing.
Management commentary on US sales outlook, margin outlook, and a shift in manufacturing of key drugs like Abraxane generic and Advair generic launch will also be key.
Shares of Cipla have gained 19 percent over the last 12 months and are trading close to their 52-week high of Rs 1,185.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!

Top Budget Opinions

    Most Read

    Market Movers

    View All
    Top GainersTop Losers
    CurrencyCommodities
    CompanyPriceChng%Chng